RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea), Orphan Drug (Australia), Priority Review (United States), Breakthrough Therapy (United States)

Structure/Sequence

Sequence Code 453117726

Source: *****

Sequence Code 453117729

Source: *****

Clinical Trials associated with Efanesoctocog alfa

NCT07158606

/ Not yet recruitingPhase 4

Understanding Treatment Outcomes and Immunologic Mechanisms in ALtuviiio Immune Tolerance Induction

The goal of this clinical trial is to learn how well Altuviiio (efanesoctacog alpha) works for Immune Tolerance Induction (ITI) while using Hemlibra (emicizumab) to prevent bleeds.
Participants will be given Altuviiio for their ITI therapy and also be treated with Hemlibra as standard of care prophylaxis to prevent bleeding. The research doctor will decide how much and how often the participant will get Hemlibra.
Participants will need to attend visits for checkups and tests. These visits are divided into 4 periods:
1. A screening period - 1 visit up to 8 weeks before the Treatment Period starts
2. ITI Treatment Period - 1 Baseline Visit plus Interim visits that occur every 4 weeks for up to 52 weeks. (Some of the interim visits may be done via phone)
3. Tapering Period - 5 visits at weeks 2, 4, 8, 12 and 16
4. Ongoing Monitoring Period - 4 visits at weeks 20, 30, 40 and 50

Start Date01 Oct 2025

Sponsor / Collaborator

Versiti, Inc.

NCT06941870

/ RecruitingPhase 4

Prospective Interventional Study of Effectiveness of Efanesoctocog Alfa Prophylaxis on Synovial Hypertrophy in Patients With Hemophilia A

The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A.
The study duration for each participant is approximately 12 months.

Start Date23 Sep 2025

Sponsor / Collaborator

Sanofi

NCT06940830

/ RecruitingPhase 4

A Low-interventional Study to Evaluate Long-term Effectiveness of Real-world Prophylactic Treatment With Efanesoctocog Alfa on Joint Health in People With Haemophilia A (ALTITUDE)

The rationale for this study is to further understand and describe the long-term prophylactic effectiveness of efanesoctocog alfa in preventing joint bleeds in a real-life setting.

Start Date21 May 2025

Sponsor / Collaborator

Swedish Orphan Biovitrum AB

[+1]

100 Clinical Results associated with Efanesoctocog alfa

100 Translational Medicine associated with Efanesoctocog alfa

100 Patents (Medical) associated with Efanesoctocog alfa

Literatures (Medical) associated with Efanesoctocog alfa

01 Feb 2026·PHARMACOECONOMICS

Cost Effectiveness of Efanesoctocog Alfa Versus Factor VIII Extended Half-Life in Adolescent and Adult Patients with Hemophilia A in the USA

Article

Author: Dymond, Amy ; Green, Will ; Agirrezabal, Ion ; Arnaud, Alix

BACKGROUND AND OBJECTIVE:

Efanesoctocog alfa is a first-in-class high-sustained factor VIII therapy approved for prophylaxis, on-demand treatment, and peri-operative management of bleeding in hemophilia A. This analysis aimed to compare the cost effectiveness of efanesoctocog alfa prophylaxis with factor VIII extended half-life prophylaxis.

METHODS:

A lifetime Markov model was developed from a US payer perspective, using clinical data from an indirect treatment comparison of phase III studies and inputs derived from the literature. A cohort of patients aged ≥ 12 years with severe hemophilia A without inhibitors, who received prophylaxis using any regimen or on-demand treatment, entered the model. Outcomes included joint and non-joint bleeds, quality-adjusted life-years, total direct costs, and the incremental cost-effectiveness ratio. Costs were expressed in US dollars and inflated to January 2023 prices. Discount rates of 3% were used. One-way probabilistic and scenario analyses were conducted. The willingness-to-pay threshold was assumed at $150,000 per quality-adjusted life-year.

RESULTS:

Efanesoctocog alfa was more effective and less costly (also referred to as 'dominant') versus factor VIII extended half-life therapies, with a lower lifetime number of joint (undiscounted 34.00 vs 140.65) and non-joint (undiscounted 13.33 vs 55.99) bleeds, higher quality-adjusted life-years (24.00 vs 22.92), and lower total costs ($30,716,640 vs $32,953,485). A broad range of scenario analyses and probabilistic sensitivity analyses resulted in 100% of simulations being cost effective. Dosing level and drug costs had the largest impact on results in the deterministic sensitivity analyses.

CONCLUSIONS:

Our analysis suggests that efanesoctocog alfa was dominant versus prophylaxis with standard and elevated factor VIII extended half-life dosing regimens. Efanesoctocog alfa was associated with better joint health and, hence, contributed to fewer bleeds, lower costs, and higher quality-adjusted life-years.

01 Jan 2026·JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A phase 1, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type 2N or type 3 von Willebrand disease

Article

Author: Zilberstein, Moshe ; Yarramaneni, Abhimanyu ; Susen, Sophie ; Wong, Nancy ; Seth Chhabra, Ekta ; Santagostino, Elena ; Mamikonian, Lara ; Trossaërt, Marc ; Willemze, Annemieke

BACKGROUND:

Efanesoctocog alfa is a high-sustained factor (F)VIII replacement therapy for hemophilia A. The D'D3 domain of efanesoctocog alfa overcomes the von Willebrand factor-imposed half-life ceiling and may allow correction of reduced FVIII levels experienced by people with type 2N or type 3 von Willebrand disease (VWD).

OBJECTIVES:

This study aimed to assess the pharmacokinetics, safety, and tolerability of efanesoctocog alfa in type 2N or type 3 VWD.

METHODS:

This was a phase 1, open-label study of efanesoctocog alfa in adults with hereditary type 2N or type 3 VWD (NCT04770935). Participants received a single intravenous dose of efanesoctocog alfa (25 IU/kg). The primary end point was pharmacokinetic parameters as determined by noncompartmental analysis of efanesoctocog alfa FVIII activity using one-stage assay and capture chromogenic assay, the latter of which is more relevant in assessing FVIII levels from efanesoctocog alfa among people with VWD. Secondary end points included adverse events and FVIII inhibitor development.

RESULTS:

Six participants were assessed (type 2N, n = 2; type 3, n = 4). One dose of efanesoctocog alfa of 25 IU/kg maintained FVIII activity levels of >1 IU/dL up to 10 days postdose. Mean baseline-corrected FVIII activity levels were maintained at >40 and >10 IU/dL up to 1 day and 4 days postdose, respectively, per capture chromogenic assay. Mean (standard deviation) t_1/2z was 49.0 (10.2) hours. Efanesoctocog alfa was well tolerated. FVIII inhibitors or antidrug antibodies were not detected.

CONCLUSION:

Efanesoctocog alfa is well-tolerated and maintains high FVIII activity levels for a prolonged period in patients with type 2N or type 3 VWD.

01 Jan 2026·Therapeutic Advances in Hematology

Outcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysis

Article

Author: Susen, Sophie ; Kulkarni, Roshni ; Nogami, Keiji ; Khan, Umer ; Santagostino, Elena ; Bystrická, Linda ; Konkle, Barbara ; Chowdary, Pratima ; Peyvandi, Flora ; Dumont, Jennifer ; Willemze, Annemieke

Background::

Efanesoctocog alfa is a first-in-class high-sustained factor VIII (FVIII) replacement therapy. In the phase III XTEND-1 (NCT04161495) study, once-weekly efanesoctocog alfa prophylaxis (50 IU/kg) was well-tolerated and achieved high-sustained factor levels in the normal to near-normal range (>40%) for most of the week.

Objective::

To report outcomes in previously treated participants with severe haemophilia A aged ⩾12 years from an observational study who switched to efanesoctocog alfa prophylaxis during XTEND-1.

Design::

Paired assessment of participants from an observational study who enrolled in the phase III XTEND-1 study.

Methods::

Seventy-eight participants switched from marketed standard half-life (SHL) or extended half-life (EHL) FVIII prophylaxis to once-weekly efanesoctocog alfa prophylaxis (50 IU/kg). Endpoints included annualized bleed rates (ABRs), treatment of bleeding episodes, injection frequency and FVIII consumption.

Results::

Pre-study, 44 (56%) and 34 (44%) participants received SHL FVIII or EHL FVIII prophylaxis, respectively. In the overall population, a significant reduction in ABR from 2.96 to 0.69 ( p < 0.0001) was observed following the switch to efanesoctocog alfa prophylaxis as well as reductions in spontaneous, traumatic, joint and spontaneous joint ABRs ( p < 0.0001). Significant reductions in mean weekly injection frequency were observed, from 2.8 to 1.0 in the SHL FVIII cohort ( p < 0.0001) and from 1.8 to 1.0 in the EHL FVIII cohort ( p < 0.0001). Mean annualized factor consumption reduced by 47% in the SHL FVIII cohort and 30% in the EHL FVIII cohort.

Conclusion::

Collectively, the results of this post hoc analysis demonstrate the benefits of once-weekly efanesoctocog alfa prophylaxis over SHL or EHL FVIII prophylaxis on bleed rates, injection frequency and consumption.

Trial registration::

Observational study: 242HA201/OBS16221; XTEND-1: NCT04161495 ( https://clinicaltrials.gov/study/NCT04161495 ).

136

News (Medical) associated with Efanesoctocog alfa

18 Feb 2026

·www.prnewswire.com

Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030

STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today hosts its Capital Markets Day, where senior management will provide an update on the company's strategy and outline its new mid-term outlook, aiming to achieve SEK 55bn revenue by 2030, while building a resilient platform for sustained growth beyond 2030. Sobi aims to have an adjusted EBITA margin in the upper 30s percentage of revenue by 2030. Sobi has delivered strong and profitable growth in recent years, transforming and diversifying its portfolio and positioning the company to deliver on six major launches. Additionally, Sobi is advancing priority development programs enabling longer term growth and continuing its international expansion. "Sobi today is a stronger, more global and more scientifically driven company," says Guido Oelkers, CEO of Sobi. "We have delivered on our commitments, built a diversified, robust foundation for future growth, and are entering the next phase of expansion with multiple launches and compelling opportunities to unlock growth well beyond 2030." Highlights of the Capital Markets Day Sobi shares its ambition to reach SEK 55bn in revenues by 2030, effectively doubling the company revenue driven by six major launches, continued strong performance of strategic products, and international expansion. Sobi outlines major launches either ongoing or in preparation, expected to drive the majority of growth to 2030, including Altuvoct®, Gamifant®, Aspaveli®, Tryngolza®, NASP, and pozdeutinurad, across haematology, immunology, and specialty care. Deep dives demonstrate Sobi's scientific leadership in: Uncontrolled and progressive gout and two potentially transformative treatment innovations in an area of high unmet patient needs. Severe hypertriglyceridemia, where acute pancreatitis is a major risk and a severe medical emergency, and ApoC-III inhibition with olezarsen has shown significant and meaningful reductions in acute pancreatitis risk. Precision medicine in sepsis: In biomarker-selected patients with interferon gamma-driven sepsis (the proof-of-concept EMBRACE study), Sobi will share topline data for empalumab demonstrating improvement in SOFA-based organ function (achieving primary endpoint at end of treatment in 60% patients receiving high dose emapalumab vs 40% in the standard of care plus placebo arm). High dose emapalumab additionally showed a 12-percentage point absolute mortality reduction after 28-days (40% mortality in the high dose emapalumab arm vs 52% in the standard of care plus placebo arm). Additional information provided New peak sales expectations for the following products: Haemophilia A franchise (Altuvoct and Elocta) greater than SEK 10bn, Aspaveli between SEK 7-10bn, Gamifant in HLH between SEK 5-7bn, NASP between SEK 4-6bn, Tryngolza greater than SEK 10bn, pozdeutinurad greater than SEK 10bn and Gamifant in IDS greater than SEK 10bn. R&D expenses to remain between 11-14 per cent of sales on a given year between now and 2030. Agenda in brief The Capital Markets Day includes presentations from Sobi's executive leadership on strategy, pipeline and innovation, commercial opportunities and financial outlook as well as disease deep dives with experts and leaders in their respective fields, and a concluding Q&A session. Pre-registration for online attendance: click here A recording of the presentations and supporting materials will be made available on . Sobi Sobi® is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2025 revenue amounted to SEK 28 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:00 CET on 18 February 2026. Gerard Tobin Head of Investor Relations This information was brought to you by Cision The following files are available for download: SOURCE Swedish Orphan Biovitrum AB 21% more press release views with Request a Demo

Clinical Result

03 Feb 2026

·www.prnewswire.com

Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026

STOCKHOLM, Feb. 3, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced its participation at the 19th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), taking place 3-6 February 2026 in Dublin, Ireland. At this year's meeting, Sobi will present new haemophilia data with seven scientific abstracts, including one oral presentation highlighting three years of treatment with Altuvoct from the XTEND-ed study. These presentations underscore Sobi's mission to deliver life-changing therapies for patients with rare and severe blood disorders. "At EAHAD 2026, we will share long-term data from the XTEND-ed study of Altuvoct prophylaxis in haemophilia A. After three years of treatment, Altuvoct continues to offer protection to these patients, confirming the original registrational data. The few bleeds were managed well, and the data showed no unexpected safety issues. This underscores our belief in the potential of Altuvoct," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. "Haemophilia is a very severe chronic disease. We are committed to advancing the science for people living with this condition." Summary of full Sobi data to be presented at EAHAD 202 6: About ALTUVOCT ® (efanesoctocog alfa) ALTUVOCT® (efanesoctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (HA). ALTUVOCT can be used for all age groups and any disease severity. About the Sobi and Sanofi Collaboration Sobi and Sanofi collaborate on the development and commercialisation of ALTUVOCT® (efanesoctocog alfa), or ALTUVIIIO™ in the US. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia, and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. Sanofi apply deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Sanofi's team is guided by one purpose: to chase the miracles of science to improve people's lives; this inspires Sanofi to drive progress and deliver positive impact for Sanofi's people, and the communities Sanofi serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information was brought to you by Cision The following files are available for download: 21% more press release views with Request a Demo

03 Feb 2026

·www.sobi.com

Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026

These presentations underscore Sobi’s mission to deliver life-changing therapies for patients with rare and severe blood disorders. “At EAHAD 2026, we will share long-term data from the XTEND-ed study of Altuvoct prophylaxis in haemophilia A. After three years of treatment, Altuvoct continues to offer protection to these patients, confirming the original registrational data. The few bleeds were managed well, and the data showed no unexpected safety issues. This underscores our belief in the potential of Altuvoct,” said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. “Haemophilia is a very severe chronic disease. We are committed to advancing the science for people living with this condition.” Summary of full Sobi data to be presented at EAHAD 2026: Efanesoctocog alfa Efanesoctocog alfa Efanesoctocog Alfa Prophylaxis for People with Severe Haemophilia A: Third Interim Results from the XTEND-ed Long-Term Extension Study Efanesoctocog Alfa Prophylaxis for People with Severe Haemophilia A: Third Interim Results from the XTEND-ed Long-Term Extension Study Oral Presentation Session Name: Session 10 – Late Breaking Session Date: 6 February 2026 Presentation Time: 2:30 – 2:45 PM GMT Publication Number: OR17 Oral Presentation Session Name: Session 10 – Late Breaking Session Date: 6 February 2026 Presentation Time: 2:30 – 2:45 PM GMT Publication Number: OR17 Physical Activity and Efficacy in Patients with Severe Haemophilia A Treated with Efanesoctocog Alfa: 12-Month Interim Results from FREEDOM Physical Activity and Efficacy in Patients with Severe Haemophilia A Treated with Efanesoctocog Alfa: 12-Month Interim Results from FREEDOM Poster Presentation Poster Presentation Long-Term Clinical Outcomes of Efanesoctocog Alfa in Patients with Severe Haemophilia A: European Results from the Third Interim Analysis of XTEND-ed Long-Term Clinical Outcomes of Efanesoctocog Alfa in Patients with Severe Haemophilia A: European Results from the Third Interim Analysis of XTEND-ed Poster Presentation Poster Presentation Treatment of Bleeding Episodes with Efanesoctocog Alfa in Adults, Adolescents, and Children with Severe Haemophilia A: Third Interim Analysis of the XTEND-ed Long-term Extension Study Treatment of Bleeding Episodes with Efanesoctocog Alfa in Adults, Adolescents, and Children with Severe Haemophilia A: Third Interim Analysis of the XTEND-ed Long-term Extension Study Poster Presentation Poster Presentation Haemophilia A Haemophilia A Assessment of joint health and patient-physician alignment on joint damage reports in a cohort of people with haemophilia A: real-world Insights from the CHESS III Study Assessment of joint health and patient-physician alignment on joint damage reports in a cohort of people with haemophilia A: real-world Insights from the CHESS III Study Poster Presentation Poster Presentation Clinical, Psychosocial, Quality of Life Outcomes and Patient-Physician Discrepancies in Joint Damage Reporting in a cohort of People with Haemophilia A: real-world insights from the CHESS III Study Clinical, Psychosocial, Quality of Life Outcomes and Patient-Physician Discrepancies in Joint Damage Reporting in a cohort of People with Haemophilia A: real-world insights from the CHESS III Study Poster Presentation Poster Presentation rFIXFc rFIXFc Real-World Effectiveness and Usage of rFIXFc in Haemophilia B: Final Paediatric Data from the B-MORE Study Real-World Effectiveness and Usage of rFIXFc in Haemophilia B: Final Paediatric Data from the B-MORE Study Poster Presentation Poster Presentation About ALTUVOCT ® (efanesoctocog alfa) ALTUVOCT® (efanesoctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (HA). ALTUVOCT can be used for all age groups and any disease severity. About the Sobi and Sanofi CollaborationSobi and Sanofi collaborate on the development and commercialisation of ALTUVOCT® (efanesoctocog alfa), or ALTUVIIIO™ in the US. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia, and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. Sanofi apply deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Sanofi’s team is guided by one purpose: to chase the miracles of science to improve people’s lives; this inspires Sanofi to drive progress and deliver positive impact for Sanofi’s people, and the communities Sanofi serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care. We contribute to societies by improving access to treatment of rare diseases. Find out more about our business and financial performance. Here we present our most recent press releases, stories, news articles, and images. Every day, we work actively to find better ways to understand and meet patient needs.

Clinical ResultPhase 3

100 Deals associated with Efanesoctocog alfa

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hemophilia A	United States	Bioverativ, Inc.	22 Feb 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemorrhage	Phase 3	United States	Biogen, Inc.	23 Feb 2021
Hemorrhage	Phase 3	United States	Sanofi (China) Investment Co. Ltd.	23 Feb 2021
Hemorrhage	Phase 3	United States	Bioverativ Therapeutics, Inc.	23 Feb 2021
Hemorrhage	Phase 3	Belgium	Bioverativ Therapeutics, Inc.	23 Feb 2021
Hemorrhage	Phase 3	Belgium	Biogen, Inc.	23 Feb 2021
Hemorrhage	Phase 3	Belgium	Sanofi (China) Investment Co. Ltd.	23 Feb 2021
Hemorrhage	Phase 3	Bulgaria	Bioverativ Therapeutics, Inc.	23 Feb 2021
Hemorrhage	Phase 3	Bulgaria	Biogen, Inc.	23 Feb 2021
Hemorrhage	Phase 3	Bulgaria	Sanofi (China) Investment Co. Ltd.	23 Feb 2021
Hemorrhage	Phase 3	Canada	Bioverativ Therapeutics, Inc.	23 Feb 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04161495 (XTEND-1, Pubmed \| Ther Adv Hematol)	Phase 3	Hemophilia A	78	Efanesoctocog alfa	swpwiavndd(laoewpwktb) = eawzpddbma bfxmyexjms (gluwbzobty ) View more	Positive	01 Jan 2026
NCT04161495 (XTEND-1, Pubmed \| Ther Adv Hematol)	Phase 3	Hemophilia A	78	Efanesoctocog alfa	swpwiavndd(laoewpwktb) = hgkgafbysj bfxmyexjms (gluwbzobty ) View more	Positive	01 Jan 2026
ASH2025	Not Applicable	Hemophilia A	80	Efanesoctocog alfa	volfdkmgji(kvjplzwxjl) = huapedwsnd tsxugzxpcs (jizmezewjt ) View more	Positive	06 Dec 2025
NCT04644575 (XTEND-ed, ASH2025)	Phase 3	Hemophilia A	217	Efanesoctocog alfa (Adults and adolescents)	sutowvoprp(rwcnozjxxs) = vpciaygcqa owywupqlug (doldaxjvvb ) View more	Positive	06 Dec 2025
NCT04644575 (XTEND-ed, ASH2025)	Phase 3	Hemophilia A	217	Efanesoctocog alfa (children)	sutowvoprp(qwkgduceqt) = jxeqepnmvj ojggfnmwqz (hhhqbfwejh ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Hemophilia A	41	Efanesoctocog alfa	elupcimxfz(durwxnuhtt) = qumefcbgof cpizcypmjh (qtnsybvymm, 1.07) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Hemophilia A	41	Efanesoctocog alfa	elupcimxfz(arpvhjwdst) = nmavynbdef uclytywdus (vesbywfvlb, 1.57)	Positive	06 Dec 2025
NCT04161495 \| NCT04759131 (XTEND-1 and XTEND-Kids, Pubmed \| Haemophilia)	Phase 3	Hemophilia A factor VIII (FVIII) activity levels	-	Efanesoctocog alfa 50 IU/kg	hrnvdvaxli(klwysklnqw) = qirqfkjulg wauzyskydg (ehjdkhyfyo, 45 - 361)	Positive	01 May 2025
NCT04644575 (XTEND-ed, ASH2024)	-	Hemophilia A	146	Efanesoctocog alfa	wgsgfqkfuq(ogkxbkjwdi) = vjvrvpraoh pwpirquzyj (lzcethpqqj ) View more	Positive	09 Dec 2024
ASH2024	Not Applicable	Hemophilia A	-	Efanesoctocog Alfa	blanskftgs(tieplkctmg) = One PwHA experienced an infusion reaction after the fourth dose txzygqrrug (bwogqyfetl ) View more	-	07 Dec 2024
NCT04161495 (XTEND-1, Pubmed \| Clin Ther)	Phase 3	Hemophilia A	159	Efanesoctocog alfa prophylaxis 50 IU/kg for 52 weeks	wovucytric(qskjseepnk) = ixpqmzykyb jltxjqoted (gfgnqhpfls ) View more	Positive	01 Dec 2024
NCT04759131 (XTEND-Kids, PRNewswire) Manual	Phase 3	Hemophilia A	73	ALTUVOCT	dbabgjgdwj(ylhqstejow) = cyaszrnwto wjmabcpmtb (jybfgxuufk, 0.42–0.90) View more	Positive	18 Jul 2024
NCT04759131 (XTEND-Kids, Pubmed \| N Engl J Med)	Phase 3	Hemophilia A	74	Efanesoctocog alfa	xznwmulspj(epkzisgtyp) = Most adverse events were nonserious. No serious adverse events that were assessed by the investigator as being related to efanesoctocog alfa were reported. xnntxkzbhz (xhgszxkwbx )	Positive	18 Jul 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis